Evolocumab + Atorvastatin + Placebo to Evolocumab + Placebo to Atorvastatin
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Primary Hyperlipidemia and Mixed Dyslipidemia
Conditions
Primary Hyperlipidemia and Mixed Dyslipidemia
Trial Timeline
Jul 8, 2014 → Mar 5, 2015
NCT ID
NCT02189837About Evolocumab + Atorvastatin + Placebo to Evolocumab + Placebo to Atorvastatin
Evolocumab + Atorvastatin + Placebo to Evolocumab + Placebo to Atorvastatin is a phase 3 stage product being developed by Amgen for Primary Hyperlipidemia and Mixed Dyslipidemia. The current trial status is completed. This product is registered under clinical trial identifier NCT02189837. Target conditions include Primary Hyperlipidemia and Mixed Dyslipidemia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02189837 | Phase 3 | Completed |
Competing Products
20 competing products in Primary Hyperlipidemia and Mixed Dyslipidemia